A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country

被引：68

作者：

Verma, S. P. ^{[1
]}

Dutta, T. K. ^{[2
]}

Mahadevan, S. ^{[3
]}

Nalini, P. ^{[3
]}

Basu, D. ^{[4
]}

Biswal, N.

Ramesh, A. ^{[5
]}

Charles, D. ^{[1
]}

Vinod, K. V. ^{[6
]}

Kumar, K. T. Harichandra ^{[7
]}

机构：

[1] Jawaharlal Inst Post Grad Med Educ & Res JIPMER, Clin Haematol, Pondicherry 605006, India

[2] Jawaharlal Inst Post Grad Med Educ & Res JIPMER, Div Clin Haematol, Med, Pondicherry, India

[3] Jawaharlal Inst Post Grad Med Educ & Res JIPMER, Pediat, Pondicherry, India

[4] Jawaharlal Inst Post Grad Med Educ & Res JIPMER, Pathol, Pondicherry, India

[5] Jawaharlal Inst Post Grad Med Educ & Res JIPMER, Radiol, Pondicherry, India

[6] Jawaharlal Inst Post Grad Med Educ & Res JIPMER, Med, Pondicherry, India

[7] Jawaharlal Inst Post Grad Med Educ & Res JIPMER, Biometr, Pondicherry, India

来源：

HAEMOPHILIA | 2016年 / 22卷 / 03期

关键词：

episodic treatment; haemarthrosis; haemophilia A; prophylaxis; CHILDREN; ARTHROPATHY;

D O I：

10.1111/hae.12838

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Current factor prophylaxis strategy practised in developed countries is not feasible in resource constraint developing countries like India. Aim: The aim of this study was to investigate the efficacy and safety of very low-dose factor prophylaxis in India. Methods: Children of 1-10 years of age with severe haemophilia were randomized to Prophylaxis group and Episodic (On demand) group. Children in prophylaxis group received very low-dose factor VIII (FVIII) concentrate, i.e. 10 units kg(-1) body weights on 2 days a week. Episodic group received factor concentrate in standard recommended doses. The study period was 11.5 months. Results: In total 21 children were enrolled in this study, 11 assigned to prophylaxis and 10 to episodic group. Children on prophylaxis had 11 joint bleeds in comparison to 57 joint bleeds in episodic group. Mean number of haemarthrosis per patient per month were 0.08 (0.08 +/- 0.13) in prophylaxis group compared to 0.48 (0.48 +/- 0.34) in episodic group (P < 0.05). Total FVIII consumption was 87.51 and 56.32 units kg(-1) month(-1) in prophylaxis and episodic group respectively (P = ns). Overall median hospital emergency visits were 1 day in prophylaxis group and 9 days in episodic group (P = 0.05). Median days of absenteeism from school were 25 days in episodic group and 3 days in prophylaxis group (P < 0.05). No significant complications were noted in prophylaxis group and compliance was 98%. Conclusion: To conclude, low-dose FVIII prophylaxis is cost effective, efficacious and a safe method of preventing joint bleeds and consequent joint damages.

引用

页码：342 / 348

页数：7

共 20 条

[1] Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized [J].

Astermark, J ;

Petrini, P ;

Tengborn, L ;

Schulman, S ;

Ljung, R ;

Berntorp, E .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :1109-1113

[2] Survival analysis of patients with haemophilia at the International Haemophilia Training Centre, Bangkok, Thailand [J].

Chuansumrit, A ;

Krasaesub, S ;

Angchaisuksiri, P ;

Hathirat, P ;

Isarangkura, P .

HAEMOPHILIA, 2004, 10 (05) :542-549

[3] Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study [J].

Feldman, BM ;

Pai, M ;

Rivard, GE ;

Israels, S ;

Poon, MC ;

Demers, C ;

Robinson, S ;

Luke, KH ;

Wu, JKM ;

Gill, K ;

Lillicrap, D ;

Babyn, P ;

McLimont, M ;

Blanchette, VS .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (06) :1228-1236

[4] Prophylaxis for severe haemophilia: clinical and economical issues [J].

Fischer, K ;

Van den Berg, M .

HAEMOPHILIA, 2003, 9 (04) :376-381

[5] Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s [J].

Fischer, Kathelijn ;

Carlsson, Katarina Steen ;

Petrini, Pia ;

Holmstrom, Margareta ;

Ljung, Rolf ;

van den Berg, H. Marijke ;

Berntorp, Erik .

BLOOD, 2013, 122 (07) :1129-1136

[6] A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) [J].

Gringeri, A. ;

Lundin, B. ;

von Mackensen, S. ;

Mantovani, L. ;

Mannucci, P. M. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (04) :700-710

[7]

Kulkarni M L, 1993, Southeast Asian J Trop Med Public Health, V24 Suppl 1, P270

[8] Haemophilia prophylaxis in young patients - a long-term follow-up [J].

Lofqvist, T ;

Nilsson, IM ;

Berntorp, E ;

Pettersson, H .

JOURNAL OF INTERNAL MEDICINE, 1997, 241 (05) :395-400

[9] Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia [J].

Manco-Johnson, Marilyn J. ;

Abshire, Thomas C. ;

Shapiro, Amy D. ;

Riske, Brenda ;

Hacker, Michele R. ;

Kilcoyne, Ray ;

Ingram, J. David ;

Manco-Johnson, Michael L. ;

Funk, Sharon ;

Jacobson, Linda ;

Valentino, Leonard A. ;

Hoots, W. Keith ;

Buchanan, George R. ;

DiMichele, Donna ;

Recht, Michael ;

Brown, Deborah ;

Leissinger, Cindy ;

Bleak, Shirley ;

Cohen, Alan ;

Mathew, Prasad ;

Matsunaga, Alison ;

Medeiros, Desiree ;

Nugent, Diane ;

Thomas, Gregory A. ;

Thompson, Alexis A. ;

McRedmond, Kevin ;

Soucie, J. Michael ;

Austin, Harlan ;

Evatt, Bruce L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (06) :535-544

[10]

NILSSON IM, 1970, BIBL HAEMATOL, P111

← 1 2 →